Year: 2023
Type: article
Abstract: Differentiated thyroid carcinomas (DTC) have an excellent prognosis, but this is sometimes overshadowed by tumor recurrences following initial treatment (approximately 15% of cases during follow-up), due to unrecognized disease extent at initial diagnosis or a more aggressive tumor biology, which are the usual risk factors. The possible sites of recurrence are local, regional, or distant. Local and regional recurrences can usually be successfully managed with surgery and radioiodine therapy, as are some isolated distant recurrences, such as bone metastases. If these treatments are not possible, other therapeutic options such as external beam radiation therapy or systemic treatments should be considered. Major advances in systemic treatments have led to improved progression-free survival in patients previously considered for palliative treatments; among these treatments, the most promising results have been achieved with tyrosine kinase inhibitors (TKI). This review attempts to give a comprehensive overview of the current treatment options suited for recurrences and the new treatments that are available in cases where salvage surgery is not possible or in cases resistant to radioiodine.
Source: Cancers
Institutions: Universidad de Oviedo, Hospital Universitario Central de Asturias, Centro de Investigación Biomédica en Red de Cáncer, Memorial Sloan Kettering Cancer Center, University of Edinburgh, Institut Gustave Roussy, Laboratoire de Phonétique et Phonologie, SIU Medicine, AC Camargo Hospital, University of Helsinki, Helsinki University Hospital, Cliniques Universitaires Saint-Luc, UCLouvain, Emory University, Winship Cancer Institute, Universitair Ziekenhuis Leuven, University of Udine
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,892
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4376115622